Infectious Disease Pharmacokinetics Lab, Emerging Pathogens Institute, University of Floridagrid.15276.37, Gainesville, Florida, USA.
Department of Pharmacotherapy and Translational Research, College of Pharmacy, University of Floridagrid.15276.37, Gainesville, Florida, USA.
Antimicrob Agents Chemother. 2022 Feb 15;66(2):e0204621. doi: 10.1128/AAC.02046-21. Epub 2021 Dec 13.
Cefepime is the second most common cephalosporin used in U.S. hospitals. We aim to develop and validate a cefepime population pharmacokinetic (PK) model and integrate it into a precision dosing tool for implementation. Two data sets (680 patients) were used to build the cefepime PK model in Pmetrics, and three data sets (34 patients) were used for the validation. A separate application data set (115 patients) was used for the implementation and validation of a precision dosing tool. The model support points and covariates were used to generate the optimal initial dose (OID). Cefepime PK was described by a two-compartment model including weight and creatinine clearance (CrCl) as covariates. The median rate of elimination was 0.30 h (adults) and 0.96 h (children), the central volume of distribution was 13.85 L, and the rate of transfer from the central to the peripheral compartments was 1.22 h and from the peripheral to the central compartments was 1.38 h. After integration in BestDose, the observed versus predicted cefepime concentration fit using the application data set was excellent ( > 0.98), and the median difference between what was observed and what BestDose predicted on a second occasion was 4%. For the OID, cefepime at a 0.5- to 1-g 4-h infusion every 8 to 24 h (q8 to 24 h) with a CrCl of <70 mL/min was needed to achieve a target range of free trough:MIC 1 to 4 at a MIC of 8 mg/L, while continuous infusion was needed for higher CrCl and weight values. In conclusion, we developed and validated a cefepime model for clinical application. The model was integrated in a precision dosing tool for implementation, and the median concentration prediction bias was 4%. The OID algorithm was provided.
头孢吡肟是美国医院第二常用的头孢菌素。我们旨在开发和验证头孢吡肟群体药代动力学(PK)模型,并将其整合到精确给药工具中以实施。两个数据集(680 名患者)用于在 Pmetrics 中建立头孢吡肟 PK 模型,三个数据集(34 名患者)用于验证。另一个应用数据集(115 名患者)用于精确给药工具的实施和验证。模型支持点和协变量用于生成最佳初始剂量(OID)。头孢吡肟 PK 采用包括体重和肌酐清除率(CrCl)作为协变量的两室模型进行描述。消除的中位数速率为 0.30h(成人)和 0.96h(儿童),中心分布容积为 13.85L,从中枢向周围室的转移率为 1.22h,从周围向中央室的转移率为 1.38h。在 BestDose 中集成后,应用数据集的观察到的与预测的头孢吡肟浓度拟合非常好(>0.98),并且第二次观察到的与 BestDose 预测的中位数差异为 4%。对于 OID,在 CrCl<70mL/min 时,需要每 8 至 24 小时(q8 至 24 小时)给予 0.5 至 1 克 4 小时输注头孢吡肟,以实现游离谷值:MIC1 至 4 的目标范围在 MIC 为 8mg/L 时,而对于更高的 CrCl 和体重值,则需要连续输注。总之,我们开发并验证了用于临床应用的头孢吡肟模型。该模型已整合到精确给药工具中以实施,中值浓度预测偏差为 4%。提供了 OID 算法。